Aridis Skyrockets on Impressive Data In Cystic Fibrosis
Market News

Aridis Skyrockets on Impressive Data In Cystic Fibrosis

Shares of biopharmaceutical company Aridis Pharmaceuticals (NASDAQ:ARDS) are soaring higher today after the company announced preliminary top-line results from a Phase 2a trial evaluating AR-501 for the treatment of cystic fibrosis.

The trial evaluated AR-501 as an inhaled aerosol for safety and pharmacokinetics in three different doses. The once-a-week regimen met the primary and secondary endpoints and no serious adverse events were observed in the participants.

Further, the drug showed an over 10-fold increase in respiratory intake of AR-501 than earlier intravenous studies. The data provides a basis for a large efficacy study and the company is now looking forward to definitive next study planning and discussions with the U.S. Food and Drug Administration as well as the European Medicines Agency.

Overall, Wall Street has a consensus price target of $10 on ARDS. This implies a nearly 20x upside in the stock but that’s after a nearly 69% slide in the share price over the past year.

Read full Disclosure

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Aridis Skyrockets on Impressive Data In Cystic Fibrosis
News On DemandStay up-to-date on market-moving news with a feed made just for youGet the App

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
RUT
Russell 2000
TNX
10-Yr-Bond
Bitcoin

Popular Articles